We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Siemens Healthineers and Carna Health Partner to Advance Kidney Care Innovation

By LabMedica International staff writers
Posted on 28 Aug 2025

Chronic kidney disease (CKD) is a growing global health challenge, particularly for high-risk and underserved populations. More...

Early detection and management are essential but often hindered by limited access to diagnostic technologies and specialist care. Addressing these gaps requires scalable solutions that integrate early screening, timely referrals, and proactive management to reduce complications and healthcare costs.

Siemens Healthineers (Forchheim, Germany) has entered into a strategic agreement with Carna Health (Boston, MA, USA) to accelerate the adoption of Carna’s artificial intelligence (AI)-enabled CKD platform and bring industry-leading point-of-care testing systems to emerging markets. The agreement aims to improve early detection and CKD management for high-risk and underserved populations by integrating Carna’s digital platforms with Siemens’ global diagnostics infrastructure.

It also aims to simplify CKD workflow processes, creating better pathways for referrals and providing timely nephrology care to improve patient outcomes while reducing healthcare costs for both patients and healthcare systems. Carna’s platform enables healthcare providers to identify and track CKD through AI-driven clinical decision support and community-based screening programs.

A population-based CKD screening program in Bermuda and Limbe, Cameroon, is currently enrolling 30,000 individuals across the Southwest and Littoral regions. The program combines Carna’s digital platform with point-of-care eGFR testing performed on the epoc Blood Analysis System from Siemens to bring scalable, tech-driven solutions and lifesaving care to communities that face challenges in accessing care.

Carna Health aims to enroll 25 million people in CKD screening programs worldwide by 2030, with plans to expand the platform to screen for other cardiometabolic diseases including diabetes. The focus is on accelerating U.S. deployment and expanding technological compatibility across diverse healthcare environments—from rural clinics to large health systems.

“We have a shared commitment to expanding digital and diagnostic testing innovation access in regions around the world where such technologies have historically been limited,” said Bethany Costello, head of Global Strategy for point of care diagnostics at Siemens Healthineers. “Combining forces will build more equitable kidney care pathways for patients globally.”

“This strategic agreement marks a turning point in the fight against CKD,” said Salvatore Viscomi, MD, Co-Founder and Chief Executive Officer of Carna Health. “By combining Carna’s AI-enabled platform with global diagnostics expertise from Siemens Healthineers, we’re delivering a unified approach to early identification, continuous monitoring, and proactive management of CKD. Together we can detect disease sooner, connect patients to care faster, and enable interventions that change health outcomes and save lives.”

Related Links:
Siemens Healthineers 
Carna Health


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.